Answers are grounded in this paper and cite their sources.
Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-beta therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.
No takes yet. Share an insight, caveat, or question.
Bielekova et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: